Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00834496
Other study ID # 08D.12
Secondary ID
Status Withdrawn
Phase N/A
First received January 30, 2009
Last updated January 11, 2017
Start date January 2009
Est. completion date January 2010

Study information

Verified date January 2017
Source Thomas Jefferson University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Observational

Clinical Trial Summary

Sirolimus can be safely switched as early as 90 days after liver transplantation with excellent tolerability and amelioration of the calcineurin inhibitor toxicity that initiated the switch.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 2010
Est. primary completion date January 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Adult (18 years or older) patients undergoing liver transplantation at Thomas Jefferson University Hospital.

2. Diagnosed with at least one of the following CNI side effects 90-180 days post transplantation:

1. CNI renal toxicity. Any liver transplant recipient who has elevated creatinine level (greater than 1.4 mg/dl) and impaired creatinine clearance (MDRD) of 40-60 ml/minute or decreased by 15% compared to baseline in the setting of having a therapeutic CNI level, without suspicion of acute or chronic allograft rejection.

2. Hepatic fibrosis on biopsy. Any patient who has fibrosis seen on liver biopsy with LFT's 2 times the upper normal limit.

3. CNI neurologic toxicity. Any patient who has significant neurological side effects from CNIs. This will include the following: seizures not secondary to an epileptogenic focus or any metabolic derangement; alteration of speech ranging from aphasia to slurred speech; inability to be awake and alert.

4. Post transplant diabetes. Any patient who has developed diabetes after transplant and in whom CNIs are thought to be contributing to poor glycemic control.

3. Signed informed consent at approximately 90 -180 days post transplantation.

Exclusion Criteria:

1. Invasive/surgical therapy within 2 weeks of the 90-180 day post transplantation conversion. (e.g. patients with T-tubes would not be eligible for the study because the T-tube removal will coincide with the conversion date).

2. Open surgical wound at 90-180 days post transplantation.

3. Acute cellular rejection during the first 90-180 days post transplantation.

4. Re-transplants or multiple-organ transplants.

5. Active infection.

6. Pregnancy.

7. Malignancy within 3 years prior to liver transplantation (except adequately treated basal cell carcinoma). Patients with HCC prior to transplant will not be excluded.

8. Total cholesterol >300 mg/dl on medical treatment or triglycerides >150 mg/dl at 90-180 days post transplantation.

9. White blood cell count <3,000/mm3 or platelet count <100,000/mm3 at 90-180 days post transplantation.

10. Ascites.

11. Patients on chemotherapy.

12. Urine protein/creatinine ration > 0.5

Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Procedure:
Liver biopsy
percutaneous liver biopsy

Locations

Country Name City State
United States THomas Jefferson University and Hospital Philadelphia Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Thomas Jefferson University Wyeth is now a wholly owned subsidiary of Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary objective is that acute cellular rejection following a switch to sirolimus will be comparable to the historical rate at our center under calcineurin inhibitors of around 5% for post liver transplant recipients. 12 months No
See also
  Status Clinical Trial Phase
Completed NCT05510596 - Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome N/A
Completed NCT01399372 - Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma Phase 2
Completed NCT01196442 - Electrical Stimulation Pain Therapy in Treating Chronic Pain and Numbness Caused By Chemotherapy in Patients With Cancer N/A
Completed NCT00775645 - S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy Phase 3
Recruiting NCT00884767 - Biomarkers in Predicting Neurotoxicity in Patients With Colorectal Cancer Receiving Oxaliplatin Phase 2
Recruiting NCT03330964 - Clinical Trial of Electroacupuncture Stimulation on Prevention and Treatment of Oxaliplatin Neurotoxicity N/A
Active, not recruiting NCT04150913 - A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity Phase 2
Completed NCT01417507 - Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery N/A
Completed NCT00471445 - Topical Amitriptyline and Ketamine Cream in Treating Peripheral Neuropathy Caused by Chemotherapy in Cancer Patients Phase 3
Completed NCT00365768 - Glutamine in Treating Neuropathy Caused by Vincristine in Young Patients With Lymphoma, Leukemia, or Solid Tumors Phase 2
Withdrawn NCT00734773 - Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL Phase 0
Completed NCT00305799 - Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors N/A
Completed NCT00018967 - Carboxypeptidase-G2 in Treating Nervous System Toxic Effects in Patients Given an Overdose of Intrathecal Methotrexate N/A
Active, not recruiting NCT00978458 - Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Phase 3
Completed NCT05094154 - Effect of Antibiotic Choice On ReNal Outcomes (ACORN) Phase 4
Completed NCT02486198 - Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer Phase 3
Not yet recruiting NCT05798884 - Electro-acupuncture for the Prevention and Treatment of Oxaliplatin-induced Neurotoxicity in Colorectal Cancer Patients N/A
Completed NCT02864030 - PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment Phase 4
Completed NCT00755313 - Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer N/A
Completed NCT00369564 - Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer Phase 3